Literature DB >> 5157529

Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.

L O Farnebo, K Fuxe, M Goldstein, B Hamberger, U Ungerstedt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5157529     DOI: 10.1016/0014-2999(71)90053-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  20 in total

Review 1.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

2.  Ultrastructural evidence of amantadine and amphetamine noradrenaline releasing action.

Authors:  E Pita; N Perez
Journal:  Experientia       Date:  1977-01-15

3.  Uptake of 14C-tyramine and release of extravesicular 3H-noradrenaline in isolated perfused rabbit hearts.

Authors:  H Bönisch; E Rodrigues-Pereira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-07       Impact factor: 3.000

4.  Amantadine modulates phencyclidine binding site sensitivity in rat brain.

Authors:  R Quirion; C B Pert
Journal:  Experientia       Date:  1982-08-15

5.  Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.

Authors:  J D Parkes; R C Baxter; C D Marsden; J E Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

6.  Effect of chronic drug treatment on intestinal membrane transport of 14 C-L-dopa.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1972-12       Impact factor: 8.739

7.  In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson.

Authors:  W Wesemann; G Dette-Wildenhahn; H Fellehner
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

8.  Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

Authors:  G M Pacifici; M Nardini; P Ferrari; R Latini; C Fieschi; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

9.  The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954.

Authors:  D M Coward; N S Doggett
Journal:  Psychopharmacology (Berl)       Date:  1977-04-29       Impact factor: 4.530

10.  Drugs for Parkinson's disease reduce tremor induced by physostigmine.

Authors:  P Gothóni; M Lehtinen; M Fincke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.